Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 1;13:725679. doi: 10.3389/fimmu.2022.725679

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Liu, Lin, Wang, Zheng, Gao, Huang, Chen, Xiong, Lan, Chen, Si and Chen

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Association between survival and CCND1 amplification in melanoma patients after treatment with ICIs in the MSKCC-IO cohort (n=231). (A) The relationship between survival and CCND1 amplification in the MSKCC-IO cohort. (B) The correlation between TMB and CCND1 amplification in samples from patients with melanoma included in the MSKCC-IO cohort (n=232). (C) Hazard ratio of CCND1 status across melanoma patients with different level of TMB in the MSKCC-IO cohort (n=232). (D) Kaplan-Meier survival analysis of melanoma patients in the top 20% TMB within each histology in the MSKCC-IO TMB-high subgroup (n=51). ^aThe MSKCC-IO cohort included data from patients in the MSKCC database who had received at least one dose of ICIs. ICI, immune checkpoint inhibitor; MSKCC, the Memorial Sloan Kettering Cancer Center; TCGA, The Cancer Genome Atlas; TMB, tumor mutation burden.